Galapagos NV (AMS:GLPG)
 26.68
 -0.28 (-1.04%)
  Nov 4, 2025, 10:42 AM CET
Galapagos NV Revenue
Galapagos NV had revenue of 65.29M EUR in the quarter ending June 30, 2025, a decrease of -16.16%. This brings the company's revenue in the last twelve months to 275.61M, up 5.43% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm) 
 275.61M
Revenue Growth 
 +5.43%
P/S Ratio 
 6.45
Revenue / Employee 
 493.92K
Employees 
 704
Market Cap 
1.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% | 
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% | 
| Dec 31, 2022 | 241.25M | 6.87M | 2.93% | 
| Dec 31, 2021 | 234.38M | -243.67M | -50.97% | 
| Dec 31, 2020 | 478.05M | -356.85M | -42.74% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGalapagos NV News
- 11 days ago - Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors - GlobeNewsWire
 - 12 days ago - RBC Capital Raises Price Target on Galapagos (GLPG) to $28.00 | GLPG Stock News - GuruFocus
 - 13 days ago - Galapagos (GLPG) Stock Upgraded by Leerink Partners | GLPG Stock News - GuruFocus
 - 13 days ago - Galapagos (GLPG) Stock Outlook Brightens with Analyst Upgrade - GuruFocus
 - 13 days ago - Galapagos (GLPG) to Discontinue Cell Therapy Unit, Shares Fall - GuruFocus
 - 13 days ago - GILD: Galapagos Plans to Wind Down Cell Therapy Operations - GuruFocus
 - 14 days ago - Biotech firm Galapagos to wind down cell therapy business - Reuters
 - 14 days ago - Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation - Benzinga